Senior Leadership

Dror Ben-Asher, Co-Founder of RedHill, was previously with ProSeed Capital, a European corporate finance boutique. Mr. Ben-Asher is a graduate of the University of Oxford (M.Jur.) and completed LL.M. studies at Harvard University. At Harvard, Mr. Ben-Asher was also a Fulbright Scholar focusing on the pharmaceutical industry and markets, an Olin Fellow for Law, Economics and Business, and an Economics Teaching Fellow at Harvard’s Economics Department. Dror Ben-Asher received an LL.B. with distinction (First Class Honours) from the University of Leicester.

Gilead Raday previously served as interim CEO of Sepal Pharma, and as a director at TK Signal and Morria Biopharmaceuticals. He is a graduate of the University of Cambridge (M.Sc. in Bioscience Enterprise) and the Hebrew University of Jerusalem (M.Sc. Neurobiology, BSc Mathematics and Biology).

Adi Frish brings extensive business development and transactional experience to RedHill. Prior to joining RedHill, he served as VP Business Development at Medigus (TASE: MDGS). Mr. Frish was previously a partner at Y. Ben-Dror & Co. He is a graduate of Bar Ilan University (LL.M.) and Essex University (LL.B. with Honors).

Prior to joining RedHill, Guy Goldberg served as Senior Vice President of Business Operations at Eagle Pharmaceuticals, a specialty injectable drug development company, based in New Jersey. Previously, Mr. Goldberg was a member of the investment team at ProQuest Investments, a healthcare focused venture capital firm. He previously served as a consultant at McKinsey & Company and holds a B.A. in Economics and Philosophy from Yale University and a J.D. from Harvard Law School.

Micha Ben Chorin has over 20 years of financial management experience with specific expertise in financing, M&A and international operations. He was a member of the team that built GVT (currently Telefonica Brazil). Most recently, Mr. Ben Chorin served as CFO of Pyramid Analytics and he previously served as CFO of Starhome B.V. Mr. Ben Chorin holds an M.A. and a B.A. from Tel-Aviv University and is a Certified Public Accountant.

With more than 25 years of experience in the pharmaceutical industry, Mr. Scruggs brings extensive knowledge in commercial operations and business development. He most recently served as executive vice president of business development at Salix Pharmaceuticals, Inc. (“Salix”), until its acquisition by Valeant Pharmaceuticals International, Inc. (now Bausch Health Companies Inc.). Mr. Scruggs joined Salix in 2000, after working at Oclassen Pharmaceuticals, Inc. and Watson Pharmaceuticals, Inc. At Salix, Mr. Scruggs helped build the company’s commercial organization, serving in various sales and commercial trade-related positions. He was appointed executive vice president in 2011 and was responsible for all business development activities as well as the worldwide distribution of Salix’s innovative products and intellectual property. Mr. Scruggs also served as chairperson of the board of directors of Oceana Therapeutics, Salix’s European subsidiary.

Prior to joining RedHill, Dr. Fathi served as Director of Research Operations at XTL Biopharmaceuticals. He was previously at VivoQuest, PharmaGenics, Metrigen, Enzo Biochem and the Harvard Institute of Chemistry and Cell Biology. Dr. Fathi graduated from Rutgers University (Ph.D. and Post-Doctoral Fellow) and Texas Tech University (BSc).

David Wasserman has over 33 years of experience in the pharmaceutical industry, with extensive expertise in domestic and global business Alliance Management, licensing and international distribution activities. Prior to joining RedHill, Mr. Wasserman served as Executive Director Global Business Alliance Management at Salix Pharmaceuticals, managing various areas of the Business Development Search and Evaluation Team. Mr. Wasserman has extensive experience in start-up and historically established companies and strong proficiencies in due diligence, business analytics, and product portfolio life cycle management. Prior to joining Salix, Mr. Wasserman was Director of Sales Training and Career Development at Watson Pharmaceuticals (now Actavis) and the Dermatology Division at Glaxo PLC. Mr. Wasserman has also help positions as a Regional Sales Manager at Astellas, PharmaDerm, and Oclassen Pharmaceuticals.

June Almenoff, M.D., Ph.D., FACP is an accomplished executive with over twenty years’ experience in the pharmaceutical industry. Dr. Almenoff served as Principal Executive Officer and Chief Medical Officer of Furiex Pharmaceuticals, leading the development of Viberzi® up to its approval in 2015. Prior to joining Furiex, Dr. Almenoff worked at GlaxoSmithKline (GSK), where she held various positions of increasing responsibility. During her twelve years at GSK, Dr. Almenoff served as Vice President in the Clinical Safety organization and led the development of pioneering systems for minimizing risk in drug development. Dr. Almenoff was appointed as a member of RedHill’s Scientific Advisory Board in 2016. She has recently served as a Board member and advisor to numerous biopharma companies. She received her B.A. cum laude from Smith College and graduated with AOA honors from the M.D.-Ph.D. program at the Mt. Sinai School of Medicine. She completed post-graduate medical training at Stanford University Medical Center and served on the faculty of Duke University School of Medicine.

Dr. Levitt is a Board Certified Medical Oncologist and Internist in the US and is Specialty Certified as an Oncologist (Medical and Radiation) and Internist in Israel. Prior to joining RedHill, Dr. Levitt served as Global Head of the Oncology Therapeutic Area, Global Business Development at Teva and helped lead Teva to the establishment of an Oncology Franchise with the acquisition of Cephalon. He serves on the Board of Directors of EnGeneIC, Ltd, an Australian nanoparticle company. Dr. Levitt also previously served as Head of the Lung Cancer Unit at Sheba Medical Center and has held positions at Inotek Pharmaceuticals and served as Director of the University of Pittsburgh Cancer Institute Pulmonary Oncology Program and as Assistant Professor of Medicine. He was a KOL in lung cancer and a leader in the Eastern Cooperative Oncology Group (ECOG) and the National Surgical Adjuvant Breast and Bowel Project. Dr. Levitt completed his internship and residency in Internal Medicine at Hahnemann University Hospital and his fellowship in Medical Oncology at the National Cancer Institute (NIH).

Rob Jackson has a strong track record of success leading and executing new product launches and brand management across the pharmaceutical and medical device industries. Prior to joining RedHill, Mr. Jackson served in commercial leadership roles at Bioventus, most recently as the National Director of Market Access for the surgical business unit. Mr. Jackson served as Group Brand Director for the ulcerative colitis and purgative franchises at Salix Pharmaceuticals and alsoled new product launches for Vicuron Pharmaceuticals and Merck & Co. Mr. Jackson received his Bachelor of Science in Biology at Fitchburg State College and an MBA from Ball State University.

Patricia Anderson has over 30 years of experience in regulatory affairs, developing numerous successful submissions to regulatory agencies across North America and Europe. Prior to joining RedHill, Ms. Anderson served as VP of Regulatory Services at MAPI SRS and as a member of the Executive Steering Committee for SRS, responsible for the business unit for regulatory consulting. She also served in various regulatory affairs positions at PharmApprove International Regulatory Consultants, Hyal Pharmaceutical Corporation and Bayer Canada. Ms. Anderson graduated with a B.Sc. in Biology from York University and a M.Sc. in Regulatory Affairs from University of Hertfordshire. Ms. Anderson received a Regulatory Affairs Certification (RAC) from the Regulatory Affairs Professional Society and Ms. Anderson was also honored as a Fellow of the Regulatory Affairs Professional Society.

Steven Thomasian has over ten years of experience in supply chain, supplier management and developing alliance and supply chain functionality. Mr. Thomasian most recently held the position of Vice President of Supply Chain at Kala Pharmaceuticals and, prior to that, at Cempra Pharmaceuticals. Mr. Thomasian served as Executive Director of Global Supply Chain and Logistics at Salix Pharmaceuticals, and a Director of Supply Chain at Orexigen Therapeutics. Mr. Thomasian received his Bachelor of Science in Marketing and Purchasing and Materials Management in the University of Massachusetts Lowell and completed seminars on pharmaceuticals supply chains.

Reginald Williams, RedHill’s VP of Quality, is an accomplished executive with expertise in strategic planning, implementation and oversight of quality assurance programs. Mr. Williams has over 20 years’ experience in the pharmaceutical industry building sustainable quality organizations. Prior to joining RedHill, Mr. Williams served as Director of Quality Assurance at Humacyte Inc. where he led the development of the company’s quality assurance program and the overall strategic planning for quality assurance, validation and quality control. Mr. Williams served for 10 years as Senior Manager Quality Operations at Salix Pharmaceuticals where he led quality oversight for 12 drug products. Mr. Williams also previously served as Associate Director of QA, GMP/GLP at Chimerix Inc. and in various Quality leadership positions at Amgen, Eli Lilly and Merck & Co.

Michelle Snelling has over 20 years of experience in Human Resources in the pharmaceutical industry. Prior to joining RedHill, Ms. Snelling spent 15 years at Salix Pharmaceuticals in progressively more senior HR roles; building HR functions, processes, and leading teams. In addition to providing HR management services, Ms. Snelling serves as a consultant and advisor to all levels of management on HR-related processes and issues. She is a Certified Professional in Human Resources (PHR^®) and a SHRM Certified Professional (SHRM-CP^®).

Patrick McLean, our dear friend and colleague, passed away in February 2021. He will be greatly missed.